The RNASET2 antibody is a crucial tool for studying the RNASET2 protein, a member of the evolutionarily conserved ribonuclease T2 family. RNASET2 encodes a glycoprotein with ribonuclease activity, implicated in diverse biological processes, including immune modulation, tumor suppression, and cellular stress response. It is secreted into the extracellular matrix and interacts with pathways regulating angiogenesis, inflammation, and oxidative stress. Dysregulation of RNASET2 has been linked to cancer progression, autoimmune disorders, and neurodegenerative diseases like cerebral cavernous malformations (CCMs).
RNASET2 antibodies are primarily used in research to detect and quantify protein expression via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies aid in elucidating RNASET2's role in tumor microenvironment regulation, where it acts as a tumor suppressor by inhibiting endothelial cell proliferation and modulating macrophage polarization. Studies also explore its neuroprotective functions and involvement in lysosomal pathways.
Commercially available RNASET2 antibodies are typically raised in hosts like rabbits or mice using recombinant protein immunogens. Both polyclonal and monoclonal variants exist, with specificity validated across human, mouse, and rat homologs. Researchers utilize these antibodies to investigate RNASET2's clinical relevance, including its potential as a biomarker for cancer prognosis or therapeutic targeting. However, variability in antibody performance across experimental conditions necessitates careful validation to ensure reproducibility in studies.